CL2020002561A1 - Composiciones y métodos para el tratamiento de la distrofia macular - Google Patents

Composiciones y métodos para el tratamiento de la distrofia macular

Info

Publication number
CL2020002561A1
CL2020002561A1 CL2020002561A CL2020002561A CL2020002561A1 CL 2020002561 A1 CL2020002561 A1 CL 2020002561A1 CL 2020002561 A CL2020002561 A CL 2020002561A CL 2020002561 A CL2020002561 A CL 2020002561A CL 2020002561 A1 CL2020002561 A1 CL 2020002561A1
Authority
CL
Chile
Prior art keywords
macular dystrophy
compositions
treatment
methods
subject
Prior art date
Application number
CL2020002561A
Other languages
English (en)
Inventor
De La Camara Cristina Martinez-Fernandez
Robert Maclaren
Gregory S Robinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2020002561A1 publication Critical patent/CL2020002561A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La divulgación proporciona una composición que comprende una secuencia de ácido nucleico que comprende (a) una secuencia que codifica un promotor de distrofia macular viteliforme 2 (VMD2), y (b) una secuencia que codifica una proteína bestrofina-1 (BEST1), así como el uso de estas composiciones para el tratamiento de la distrofia macular en un sujeto, que comprende la administración de la composición al ojo de un sujeto por una via subretiniana o supracoroidea.
CL2020002561A 2018-04-05 2020-10-02 Composiciones y métodos para el tratamiento de la distrofia macular CL2020002561A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862653131P 2018-04-05 2018-04-05

Publications (1)

Publication Number Publication Date
CL2020002561A1 true CL2020002561A1 (es) 2021-04-23

Family

ID=66223872

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002561A CL2020002561A1 (es) 2018-04-05 2020-10-02 Composiciones y métodos para el tratamiento de la distrofia macular

Country Status (21)

Country Link
US (2) US20190307900A1 (es)
EP (1) EP3775233A1 (es)
JP (1) JP2021520232A (es)
KR (1) KR20210005040A (es)
CN (1) CN113056561A (es)
AU (1) AU2019247864A1 (es)
BR (1) BR112020020204A2 (es)
CA (1) CA3096088A1 (es)
CL (1) CL2020002561A1 (es)
CO (1) CO2020013690A2 (es)
EA (1) EA202092069A1 (es)
IL (1) IL277779A (es)
JO (1) JOP20200253A1 (es)
MA (1) MA52199A (es)
MX (1) MX2020010477A (es)
PE (1) PE20210918A1 (es)
PH (1) PH12020551641A1 (es)
RU (1) RU2020132890A (es)
SG (1) SG11202009759SA (es)
TW (1) TW202003052A (es)
WO (1) WO2019195727A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047476A1 (en) * 2018-08-31 2020-03-05 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
EP3870148A4 (en) 2018-10-25 2022-11-09 Takeda Pharmaceutical Company Limited AAV TRIPLE PLASMID SYSTEM
WO2020140007A1 (en) * 2018-12-28 2020-07-02 University Of Rochester Gene therapy for best1 dominant mutations
BR112022017182A2 (pt) * 2020-02-28 2022-11-08 Univ Pennsylvania Tratamento de bestrofinopatias autossômicas recessivas e métodos para avaliação das mesmas
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
WO2024064608A2 (en) * 2022-09-20 2024-03-28 Intergalactic Therapeutics, Inc. Best1 vectors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009153563A1 (en) * 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
CA2930282C (en) * 2013-11-20 2024-09-10 Universita Degli Studi Di Napoli Federico Ii Artificial DNA-Binding Proteins and Their Uses
KR102281881B1 (ko) * 2013-12-06 2021-07-27 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
CA2979120A1 (en) * 2015-03-03 2016-09-09 Fondazione Telethon Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
EP3374494A4 (en) * 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY

Also Published As

Publication number Publication date
EP3775233A1 (en) 2021-02-17
AU2019247864A1 (en) 2020-10-22
WO2019195727A1 (en) 2019-10-10
MA52199A (fr) 2021-02-17
BR112020020204A2 (pt) 2021-01-19
PE20210918A1 (es) 2021-05-19
US20190307900A1 (en) 2019-10-10
JP2021520232A (ja) 2021-08-19
IL277779A (en) 2020-11-30
PH12020551641A1 (en) 2021-07-26
US20230149566A1 (en) 2023-05-18
MX2020010477A (es) 2021-03-02
JOP20200253A1 (ar) 2020-10-04
SG11202009759SA (en) 2020-10-29
CN113056561A (zh) 2021-06-29
RU2020132890A (ru) 2022-05-06
KR20210005040A (ko) 2021-01-13
TW202003052A (zh) 2020-01-16
CA3096088A1 (en) 2019-10-10
CO2020013690A2 (es) 2021-04-19
EA202092069A1 (ru) 2021-03-12

Similar Documents

Publication Publication Date Title
CO2020013690A2 (es) Composiciones y métodos para el tratamiento de la distrofia macular
MX2022004786A (es) Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.
CY1125152T1 (el) Συνθεσεις και μεθοδοι για τη μειωση της νεοαγγειωσης του οφθαλμου
MX2021012862A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
EP3922260A3 (en) Insulin receptor partial agonists and glp-1 analogues
CY1121348T1 (el) Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
PH12020550051B1 (en) Glp-1 compositions and uses thereof
UY38476A (es) Inhibidores de arg1 y/o arg2
UY37997A (es) Agentes antivirales contra la hepatitis b
PE20190626A1 (es) Composiciones y metodos para modular la expresion del factor b del complemento
MX2017016518A (es) Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.
MX2019003376A (es) Tratamiento de aav de la enfermedad de huntington.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
AR071510A1 (es) Anticuerpos anti- factor d humanizados y sus usos
ECSP20057847A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2017016610A (es) Metodos de reduccion de olor.
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
AU2017256910A1 (en) Optogenetic visual restoration using Chrimson
CL2017003201A1 (es) Variantes de il-37